首页> 外文期刊>Gastrointestinal Endoscopy >Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis
【24h】

Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis

机译:比较竞争试验的有效性降低结直肠癌死亡率:网络元分析

获取原文
获取原文并翻译 | 示例
           

摘要

Traditional meta-analysis revealed that, compared with no intervention, colonoscopy reduced CRC-related mortality by 57% (relative risk [RR] 0.43; 95% confidence interval [CI], 0.33-0.58), whereas FS reduced CRC-related mortality by 40% (RR 0.60; 95% CI, 0.45-0.78), and gFOBT reduced CRC-related mortality by 18% (RR 0.82; 95% CI, 0.76-0.88). NMA demonstrated nonsignificant trends favoring colonoscopy over FS (RR 0.71; 95% CI, 0.45-1.11) and FS over gFOBT (RR 0.74; 95% CI, 0.51-1.09) for reducing CRC-related deaths. NMA-based simulations, however, revealed that colonoscopy has a 94% probability of being the most effective test for reducing CRC mortality and a 99% probability of being most effective when the analysis is restricted to screening studies.
机译:传统的荟萃分析显示,与无干预相比,结肠镜检查将CRC相关的死亡率降低57%(相对风险[RR] 0.43; 95%置信区间[CI],0.33-0.58),而FS减少了相关的CRC相关死亡率 40%(RR 0.60; 95%CI,0.45-0.78)和GFOBT将CRC相关死亡率降低18%(RR 0.82; 95%CI,0.76-0.88)。 NMA展示了优于FS(RR 0.71; 95%CI,0.45-1.11)和FFOBT(RR 0.74; 95%CI,0.51-1.09)的FS(RR 0.71; 95%CI,0.51-1.09)的无显着性趋势。 然而,基于NMA的模拟表明,结肠镜检查具有94%的概率,最有效的测试降低CRC死亡率,并且在分析限制在筛选研究时最有效的概率为99%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号